NASDAQ:OPT

Opthea Competitors

$9.98
+0.32 (+3.31 %)
(As of 04/14/2021 03:45 AM ET)
Add
Compare
Today's Range
$9.98
Now: $9.98
$9.98
50-Day Range
$8.55
MA: $9.67
$11.33
52-Week Range
$8.45
Now: $9.98
$17.86
Volume156 shs
Average Volume12,716 shs
Market Capitalization$433.70 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Opthea (NASDAQ:OPT) Vs. BCRX, SGMO, KRYS, ALVR, IMVT, and RGNX

Should you be buying OPT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Opthea, including BioCryst Pharmaceuticals (BCRX), Sangamo Therapeutics (SGMO), Krystal Biotech (KRYS), AlloVir (ALVR), Immunovant (IMVT), and REGENXBIO (RGNX).

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings for BioCryst Pharmaceuticals and Opthea, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Opthea01502.83

BioCryst Pharmaceuticals presently has a consensus price target of $12.3333, indicating a potential upside of 19.16%. Opthea has a consensus price target of $36.00, indicating a potential upside of 260.72%. Given Opthea's stronger consensus rating and higher possible upside, analysts clearly believe Opthea is more favorable than BioCryst Pharmaceuticals.

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and Opthea's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million38.03$-108,900,000.00($0.94)-11.13
OptheaN/AN/AN/AN/AN/A

Opthea has lower revenue, but higher earnings than BioCryst Pharmaceuticals.

Profitability

This table compares BioCryst Pharmaceuticals and Opthea's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
OptheaN/AN/AN/A

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Opthea beats BioCryst Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sangamo Therapeutics and Opthea, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sangamo Therapeutics02402.67
Opthea01502.83

Sangamo Therapeutics currently has a consensus price target of $20.20, indicating a potential upside of 68.47%. Opthea has a consensus price target of $36.00, indicating a potential upside of 260.72%. Given Opthea's stronger consensus rating and higher possible upside, analysts plainly believe Opthea is more favorable than Sangamo Therapeutics.

Profitability

This table compares Sangamo Therapeutics and Opthea's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sangamo Therapeutics-51.51%-16.32%-9.85%
OptheaN/AN/AN/A

Earnings & Valuation

This table compares Sangamo Therapeutics and Opthea's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sangamo Therapeutics$102.43 million16.79$-95,190,000.00($0.85)-14.08
OptheaN/AN/AN/AN/AN/A

Opthea has lower revenue, but higher earnings than Sangamo Therapeutics.

Insider & Institutional Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Opthea beats Sangamo Therapeutics on 6 of the 9 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and Krystal Biotech (NASDAQ:KRYS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Institutional and Insider Ownership

73.1% of Krystal Biotech shares are held by institutional investors. 27.4% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Opthea and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptheaN/AN/AN/A
Krystal BiotechN/A-10.72%-10.40%

Analyst Ratings

This is a summary of recent recommendations for Opthea and Krystal Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opthea01502.83
Krystal Biotech00603.00

Opthea currently has a consensus target price of $36.00, suggesting a potential upside of 260.72%. Krystal Biotech has a consensus target price of $101.00, suggesting a potential upside of 31.73%. Given Opthea's higher possible upside, research analysts plainly believe Opthea is more favorable than Krystal Biotech.

Earnings and Valuation

This table compares Opthea and Krystal Biotech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptheaN/AN/AN/AN/AN/A
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-63.83

Summary

Krystal Biotech beats Opthea on 4 of the 7 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Opthea and AlloVir, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opthea01502.83
AlloVir00403.00

Opthea currently has a consensus target price of $36.00, suggesting a potential upside of 260.72%. AlloVir has a consensus target price of $48.75, suggesting a potential upside of 101.36%. Given Opthea's higher probable upside, analysts plainly believe Opthea is more favorable than AlloVir.

Earnings & Valuation

This table compares Opthea and AlloVir's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptheaN/AN/AN/AN/AN/A
AlloVirN/AN/AN/AN/AN/A

Institutional & Insider Ownership

32.1% of AlloVir shares are owned by institutional investors. 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Opthea and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptheaN/AN/AN/A
AlloVirN/AN/AN/A

Summary

AlloVir beats Opthea on 3 of the 5 factors compared between the two stocks.

Immunovant (NASDAQ:IMVT) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Institutional & Insider Ownership

40.2% of Immunovant shares are held by institutional investors. 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Immunovant and Opthea, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunovant011402.93
Opthea01502.83

Immunovant presently has a consensus target price of $45.60, suggesting a potential upside of 184.82%. Opthea has a consensus target price of $36.00, suggesting a potential upside of 260.72%. Given Opthea's higher probable upside, analysts clearly believe Opthea is more favorable than Immunovant.

Profitability

This table compares Immunovant and Opthea's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunovantN/A-34.80%-32.38%
OptheaN/AN/AN/A

Earnings and Valuation

This table compares Immunovant and Opthea's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.42
OptheaN/AN/AN/AN/AN/A

Summary

Immunovant beats Opthea on 4 of the 7 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Profitability

This table compares Opthea and REGENXBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptheaN/AN/AN/A
REGENXBIO-63.13%-21.73%-18.74%

Analyst Ratings

This is a breakdown of current recommendations for Opthea and REGENXBIO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opthea01502.83
REGENXBIO02512.88

Opthea presently has a consensus target price of $36.00, indicating a potential upside of 260.72%. REGENXBIO has a consensus target price of $62.50, indicating a potential upside of 74.43%. Given Opthea's higher probable upside, equities research analysts plainly believe Opthea is more favorable than REGENXBIO.

Institutional and Insider Ownership

75.2% of REGENXBIO shares are held by institutional investors. 14.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Opthea and REGENXBIO's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptheaN/AN/AN/AN/AN/A
REGENXBIO$35.23 million43.21$-94,730,000.00($3.26)-10.99

Opthea has higher earnings, but lower revenue than REGENXBIO.

Summary

REGENXBIO beats Opthea on 5 of the 9 factors compared between the two stocks.


Opthea Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.46+7.4%$1.72 billion$48.83 million-13.76
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.97+5.8%$1.62 billion$102.43 million-19.95
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$76.59+6.4%$1.59 billionN/A-51.75
AlloVir logo
ALVR
AlloVir
1.4$24.05+1.6%$1.54 billionN/A0.00Increase in Short Interest
Immunovant logo
IMVT
Immunovant
1.8$16.05+3.6%$1.52 billionN/A-12.44Increase in Short Interest
News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.82+3.2%$1.47 billion$35.23 million-14.44Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$31.18+2.7%$1.41 billionN/A-17.62Gap Down
Alector logo
ALEC
Alector
1.3$18.15+3.4%$1.40 billion$21.22 million-8.14
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$35.84+13.3%$1.39 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$33.65+6.2%$1.36 billionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Translate Bio logo
TBIO
Translate Bio
1.6$18.56+6.1%$1.31 billion$7.80 million-17.35
Ocugen logo
OCGN
Ocugen
1.1$7.07+5.1%$1.26 billionN/A-4.78Increase in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$14.11+1.5%$1.16 billionN/A-3.05
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$28.60+3.1%$1.14 billion$100.56 million0.00Increase in Short Interest
Gap Down
Mesoblast logo
MESO
Mesoblast
1.4$8.82+2.0%$1.12 billion$32.16 million-10.02Analyst Upgrade
Decrease in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$35.51+0.5%$1.05 billionN/A-14.80Analyst Downgrade
Curis logo
CRIS
Curis
1.1$11.98+5.1%$1.04 billion$10 million-14.61Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.08+1.1%$1.01 billion$356.07 million6.90Unusual Options Activity
News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.52+6.2%$988.06 millionN/A0.00Increase in Short Interest
Gap Down
Scholar Rock logo
SRRK
Scholar Rock
1.5$29.45+3.8%$970.33 million$20.49 million-12.22Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.82+1.2%$921.52 millionN/A-4.27Insider Selling
Increase in Short Interest
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.40+4.0%$882.12 million$250,000.00-7.40Analyst Upgrade
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.43+6.3%$878.83 million$42.74 million-227.00Increase in Short Interest
News Coverage
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$25.88+10.1%$878.32 millionN/A0.00Analyst Report
News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.27+3.2%$875.47 million$69.89 million-4.60
Passage Bio logo
PASG
Passage Bio
1.8$16.98+7.2%$848.38 millionN/A0.00Increase in Short Interest
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$23.99+7.3%$848.17 millionN/A-9.91Analyst Report
Increase in Short Interest
Gap Down
Inhibrx logo
INBX
Inhibrx
1.6$21.82+2.1%$840.65 millionN/A0.00Decrease in Short Interest
Cellectis logo
CLLS
Cellectis
1.3$20.32+4.4%$831.22 million$22.99 million-10.81
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.67+0.1%$823.81 million$2.51 million-4.04
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$5.19+2.3%$788.22 million$1.12 million-5.24Increase in Short Interest
Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.39+3.7%$785.75 millionN/A0.00Lockup Expiration
Vaxart logo
VXRT
Vaxart
1.3$5.61+1.6%$650.07 million$9.86 million-9.51
DBV Technologies logo
DBVT
DBV Technologies
0.8$6.72+12.4%$647.15 million$14.75 million-2.88Increase in Short Interest
Gap Down
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$21.09+5.8%$643.68 million$5.78 million-9.90Insider Selling
Increase in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.3$31.02+0.8%$631.08 millionN/A0.00Lockup Expiration
News Coverage
Athira Pharma logo
ATHA
Athira Pharma
2.2$17.54+3.6%$627.33 millionN/A0.00Analyst Upgrade
Gap Down
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.01+2.9%$601.99 million$13.29 million-9.94
Compugen logo
CGEN
Compugen
1.4$8.74+0.2%$596.62 million$17.80 million-23.62Analyst Report
News Coverage
Agenus logo
AGEN
Agenus
1.6$2.72+0.4%$554.70 million$150.05 million-2.50News Coverage
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$9.24+3.6%$553.38 millionN/A-1.35
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$21.30+1.4%$544.11 millionN/A-6.14Gap Down
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.26+5.9%$529.05 millionN/A-2.55Increase in Short Interest
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.82+2.8%$488.37 million$22.24 million-4.39Increase in Short Interest
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.24+2.3%$454.86 millionN/A-8.19Increase in Short Interest
AVROBIO logo
AVRO
AVROBIO
1.7$11.38+6.4%$443.27 millionN/A-3.45
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.16+5.3%$436.22 millionN/A0.00Analyst Report
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$9.04+2.1%$433.23 million$4.36 million-3.16Analyst Downgrade
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$10.16+9.0%$419.89 million$147.87 million-3.38Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$9.06+0.4%$380.79 millionN/A0.00Analyst Report
News Coverage
Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.